Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | FFAR2 | O15552 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSPA9 | P38646 | 3/20 | 0.56 |
| ▸ | HSPA5 | P11021 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11310364 | 0.98 | LMNA (0.58) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| SCHEMBL1107000 | 0.84 | ADORA2A (0.68) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| SCHEMBL27891187 | 0.81 | FFAR2 (0.62) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| Bromide SCHEMBL11317007 | 0.80 | LMNA (0.57) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| SCHEMBL23804604 | 0.79 | LMNA (0.59) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| SCHEMBL7868173 | 0.79 | LMNA (0.56) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| SCHEMBL7876872 | 0.79 | LMNA (0.59) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| SCHEMBL12884426 | 0.78 | LMNA (0.58) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| Bromide SCHEMBL11310643 | 0.76 | LMNA (0.57) | LMNAHSD17B10FFAR2TSHRHSPA9 | |
| SCHEMBL23804606 | 0.76 | HSPA5 (0.78) | LMNAHSD17B10TSHRHSPA9HSPA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168070-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HEINE NIKLAS | 2010-07-01 | — | — | US | disclosed |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATION GMNB (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2007017511-A2 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017510-A2 | ISOPHTHALIC ACID DIAMIDES FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168070-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, ADORA3 | LMNA 582/4885HSD17B10 1258/4885FFAR2 2895/4885 |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, ADORA3 | LMNA 630/4885HSD17B10 1209/4885FFAR2 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.